Inhaltsbereich
| 96 Einträge | 1, 2, 3, 4, 5 › » |
Seite 1 / 5
 Druckansicht
|
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. |
| Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A |
| The Lancet. Oncology. 2017 Nov 13. pii: S1470-2045(17)30717-9. doi: 10.1016/S1470-2045(17)30717-9 |
| PMID: 29146401 |
| Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer. |
| Kreuzinger C, Gamperl M, Wolf A, Heinze G, Geroldinger A, Lambrechts D, Boeckx B, Smeets D, Horvat R, Aust S, Hamilton G, Zeillinger R, Cacsire Castillo-Tong D |
| Cancer letters. 2015 Apr 8. pii: S0304-3835(15)00242-6. doi: 10.1016/j.canlet.2015.03.040 |
| PMID: 25862976 |
| Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer. |
| Despierre E, Moisse M, Yesilyurt B, Sehouli J, Braicu I, Mahner S, Castillo-Tong DC, Zeillinger R, Lambrechts S, Leunen K, Amant F, Moerman P, Lambrechts D, Vergote I |
| Gynecologic oncology. 2014 Oct 2. pii: S0090-8258(14)01341-9. doi: 10.1016/j.ygyno.2014.09.014 |
| PMID: 25281495 |
| HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer - a study of the OVCAD Consortium. |
| Braicu EI, Luketina H, Richter R, Cacsire Castillo-Tong D, Lambrechts S, Mahner S, Concin N, Mentze M, Zeillinger R, Vergote I, Sehouli J |
| OncoTargets and therapy. 2014 Sep 11. doi: 10.2147/OTT.S65373. pii: ott-7-1563. pmc: PMC4166345 |
| PMID: 25246800 |
| BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD). |
| Ruscito I, Dimitrova D, Vasconcelos I, Gellhaus K, Schwachula T, Bellati F, Zeillinger R, Benedetti-Panici P, Vergote I, Mahner S, Cacsire-Tong D, Concin N, Darb-Esfahani S, Lambrechts S, Sehouli J, Olek S, Braicu EI |
| European journal of cancer (Oxford, England : 1990). 2014 Jun 2. pii: S0959-8049(14)00649-2. doi: 10.1016/j.ejca.2014.05.001 |
| PMID: 24889916 |
| Ambivalent role of pFAK-Y397 in serous ovarian cancer--a study of the OVCAD consortium. |
| Aust S, Auer K, Bachmayr-Heyda A, Denkert C, Sehouli J, Braicu I, Mahner S, Lambrechts S, Vergote I, Grimm C, Horvat R, Castillo-Tong DC, Zeillinger R, Pils D |
| Molecular cancer. 2014 Mar 21. pii: 1476-4598-13-67. doi: 10.1186/1476-4598-13-67. pmc: PMC3998046 |
| PMID: 24655477 |
| Association of TAP gene polymorphisms and risk of cervical intraepithelial neoplasia. |
| Natter C, Polterauer S, Rahhal-Schupp J, Cacsire Castillo-Tong D, Pils S, Speiser P, Zeillinger R, Heinze G, Grimm C |
| Disease markers. 2013 Jul 28. doi: 10.1155/2013/368732. pmc: PMC3774964 |
| PMID: 24288424 |
| Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium. |
| Pils D, Bachmayr-Heyda A, Auer K, Svoboda M, Auner V, Hager G, Obermayr E, Reiner A, Reinthaller A, Speiser P, Braicu I, Sehouli J, Lambrechts S, Vergote I, Mahner S, Berger A, Cacsire Castillo-Tong D, Zeillinger R |
| European journal of cancer (Oxford, England : 1990). 2013 Oct 28. pii: S0959-8049(13)00851-4. doi: 10.1016/j.ejca.2013.09.011 |
| PMID: 24176298 |
| Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium. |
| Bachmayr-Heyda A, Aust S, Heinze G, Polterauer S, Grimm C, Braicu EI, Sehouli J, Lambrechts S, Vergote I, Mahner S, Pils D, Schuster E, Thalhammer T, Horvat R, Denkert C, Zeillinger R, Castillo-Tong DC |
| BMC cancer. 2013 Sep 17. pii: 1471-2407-13-422. doi: 10.1186/1471-2407-13-422. pmc: PMC3848589 |
| PMID: 24044611 |
| Association of myeloperoxidase with ovarian cancer. |
| Castillo-Tong DC, Pils D, Heinze G, Braicu I, Sehouli J, Reinthaller A, Schuster E, Wolf A, Watrowski R, Maki RA, Zeillinger R, Reynolds WF |
| Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013 Jul 27. doi: 10.1007/s13277-013-1017-3. pmc: PMC4039294. mid: NIHMS557285 |
| PMID: 23893381 |
| A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortium. |
| Pils D, Tong D, Hager G, Obermayr E, Aust S, Heinze G, Kohl M, Schuster E, Wolf A, Sehouli J, Braicu I, Vergote I, Van Gorp T, Mahner S, Concin N, Speiser P, Zeillinger R |
| BMC cancer. 2013 Apr 3. pii: 1471-2407-13-178. doi: 10.1186/1471-2407-13-178. pmc: PMC3639192 |
| PMID: 23551967 |
| Determination of tumor-infiltrating CD8+ lymphocytes in human ovarian cancer. |
| Aust S, Bachmayr-Heyda A, Pils D, Zhao L, Tong W, Berger A, Fogel M, Thalhammer T, Sehouli J, Horvat R, Zeillinger R, Castillo-Tong DC |
| International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists. 2013 Apr 9. doi: 10.1097/PGP.0b013e31826a63f8 |
| PMID: 23518910 |
| The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer. |
| Aust S, Horak P, Pils D, Pils S, Grimm C, Horvat R, Tong D, Schmid B, Speiser P, Reinthaller A, Polterauer S |
| BMC cancer. 2013 Mar 14. pii: 1471-2407-13-115. doi: 10.1186/1471-2407-13-115. pmc: PMC3605348 |
| PMID: 23497172 |
| Expression of Bcl-2 and the antiapoptotic BAG family proteins in ovarian cancer. |
| Aust S, Pils S, Polterauer S, Horvat R, Cacsire Castillo-Tong D, Pils D, Dudek G, Schmid B, Speiser P, Reinthaller A, Grimm C |
| Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry. 2013 Nov 13. doi: 10.1097/PAI.0b013e318284a053 |
| PMID: 23455184 |
| Methylation status of TUSC3 is a prognostic factor in ovarian cancer. |
| Pils D, Horak P, Vanhara P, Anees M, Petz M, Alfanz A, Gugerell A, Wittinger M, Gleiss A, Auner V, Tong D, Zeillinger R, Braicu EI, Sehouli J, Krainer M |
| Cancer. 2012 Oct 23. doi: 10.1002/cncr.27850 |
| PMID: 23096450 |
| Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortium. |
| Obermayr E, Castillo-Tong DC, Pils D, Speiser P, Braicu I, Van Gorp T, Mahner S, Sehouli J, Vergote I, Zeillinger R |
| Gynecologic oncology. 2012 Sep 24. pii: S0090-8258(12)00777-9. doi: 10.1016/j.ygyno.2012.09.021 |
| PMID: 23017820 |
| Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortium. |
| Aust S, Bachmayr-Heyda A, Pateisky P, Tong D, Darb-Esfahani S, Denkert C, Chekerov R, Sehouli J, Mahner S, Van Gorp T, Vergote I, Speiser P, Horvat R, Zeillinger R, Pils D |
| Molecular cancer. 2012 Sep 14. pii: 1476-4598-11-69. doi: 10.1186/1476-4598-11-69. pmc: PMC3533746 |
| PMID: 22978347 |
| Validating the impact of a molecular subtype in ovarian cancer on outcomes: a study of the OVCAD Consortium. |
| Pils D, Hager G, Tong D, Aust S, Heinze G, Kohl M, Schuster E, Wolf A, Sehouli J, Braicu I, Vergote I, Cadron I, Mahner S, Hofstetter G, Speiser P, Zeillinger R |
| Cancer science. 2012 May 17. doi: 10.1111/j.1349-7006.2012.02306.x |
| PMID: 22497737 |
| Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. |
| Polterauer S, Vergote I, Concin N, Braicu I, Chekerov R, Mahner S, Woelber L, Cadron I, Van Gorp T, Zeillinger R, Castillo-Tong DC, Sehouli J |
| International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2012 Mar 6. doi: 10.1097/IGC.0b013e31823de6ae |
| PMID: 22266934 |
| Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport. |
| Svoboda M, Wlcek K, Taferner B, Hering S, Stieger B, Tong D, Zeillinger R, Thalhammer T, Jäger W |
| Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie. 2011 Jun 12. pii: S0753-3322(11)00073-4. doi: 10.1016/j.biopha.2011.04.031 |
| PMID: 21719246 |
| 96 Einträge | 1, 2, 3, 4, 5 › » |
Seite 1 / 5
Druckansicht
|
Schnellinfo
-- Initiative Krebsforschung / Krebsforschungslauf
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
